Bevurogant free base

Bevurogant is a retinoid-related orphan receptor-gamma t antagonist.

For research use only. Not for human or veterinary use.

Target ROR

Research area Inflammation/Immunology Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

Bevurogant structure

CAS No.: 1817773-66-2

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
100 mg	USD 485.00	BP-01933-100mg	In stock	Get quote
250 mg	USD 885.00	BP-01933-250mg	In stock	Get quote
500 mg	USD 1,385.00	BP-01933-500mg	In stock	Get quote
1 g	Inquire	BP-01933-1g	Inquire	Inquire

Custom Size Bulk Inquiry

Description

Bevurogant (BI 730357) is a retinoid-related orphan receptor-gamma t (RORγt) antagonist. Bevurogant can be used for the research of chronic inflammatory diseases.

Biological activity

In Vitro Bevurogant can target the Th17 cell-associated pathway, potently inhibit P-gp and potentially inhibit BCRP, and is applicable for investigating Th17-mediated inflammatory diseases such as psoriasis. In Vivo Bevurogant has a favorable safety and tolerability profile.

Identifiers

SMILES: O=C1C(NCC2=NC=C(C=C2)S(=O)(C)=O)=NC3=CN=C(N=C3N1[C@@H](C)C4CC4)C5=C(N=CN=C5C6CC6)C
InChIKey: HVVHIBHBDCYLDI-HNNXBMFYSA-N

Specifications

MW (average): 532.6170
Formula: C₂₆H₂₈N₈O₃S
CAS No.: 1817773-66-2
Physical state: Solid
Color: White to light yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO 250 mg/mL

Documents

References

[1]. BAKONYI J, et, al. Compounds as modulators of ror gamma. US20150291607A1.

[2]. Choi H, et al. The Effect of BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open-Label, Non-randomized, 2-Period Fixed-Sequence Trial in Healthy Subjects. Clin Pharmacol Drug Dev. 2024 Feb;13(2):197-207.

Same target

Search ROR

Same research area

Search Inflammation/Immunology